The Psychedelics Newsletter

Psilocybin therapy for end-of-life care supported by 79% of Canadians, Independent UK body issues response on psychedelics for anxiety, Bill aims to legalise psychedelic-assisted therapy in California.

Non-SRI patients experience positive therapeutic effects of psychedelics, Microdosing psilocybin may help compulsive behaviours, Key legal factors to consider for psychedelic clinical trials.

European Union provides first ever funding for psychedelic research, AlphaFold identifies hundreds of thousands of potential new psychedelic molecules, Study investigates if psilocybin could help chronic back pain.

MAPS PBC raises $100m and rebrands, CPT III codes for psychedelic therapies now in effect, Researching the history of psychedelic drugs

MAPS PBC raises $100m and rebrands, CPT III codes for psychedelic therapies now in effect, Researching the history of psychedelic drugs

Employment in the psychedelics industry, Non-hallucinogenic psychedelics to advance mental health care, Congress approves defence bill with $10m for psychedelics research

Psilocybin for bipolar depression, Patients call for palliative psychedelic therapy access, NDA submitted for MDMA-assisted therapy for PTSD

Mapping the effects of ketamine on the brain, Psilocybin analogue shows positive results, Psychedelic therapy programmes launch for burnout and heartbreak.

Short Wave Pharma aims to innovate eating disorder care, Volunteers called to support groundbreaking psychedelic research, Microdosing could help people with ADHD.

How to regulate psychedelics for non-medical use, Groundbreaking trial to assess real-world efficacy of MDMA therapy for PTSD, Canada recommends launch of psychedelic research programme for Veterans.